Digestive diseases include a large group of diseases of the stomach and intestines. The most common diseases are chronic gastritis and ulcerative defects. In these cases, there is a failure of the mechanism for regulating the formation of gastric juice, a violation of the ratio of the acid-peptic factor and the body's defenses, damage to the gastric mucosa with the formation of ulcerative defects and erosion.
The causes of erosive gastritis and stomach ulcers are many. In recent decades, a lot of data has appeared about the participation in the occurrence of ulcers and the maintenance of the inflammatory process in the membrane of the stomach, a gram-negative microorganism - Helicobacter pylori. The specific mobility of this bacterium allows it to move in a viscous environment, such as gastric juice. With gastritis and ulcers, this bacterium is found in most cases. It has the ability to fix and function on epithelial cells, reducing mucus production and changing its quality.
The normal state of the mucous membrane is maintained by a balance of aggressive and protective factors. Gastric mucus is a protective component that protects the mucous membrane from the aggression of hydrochloric acid. Also protective factors include normal blood supply to the stomach and its good ability to regenerate. Aggressive factors are the increased production of hydrochloric acid and pepsin, poor motility of the stomach, trauma to the membranes of the stomach and duodenum of Helicobacter pylori.
Drug treatment of gastritis and gastric ulcers is prescribed by a gastroenterologist and represents a complex of drugs whose action is aimed at irradiating Helicobacter pylori, suppressing hyperproduction of hydrochloric acid, patronage of the mucous membrane and regeneration of erosion and ulcerative defects.
One of the main drugs used in the anti-ulcer therapy complex is De-nol. In its composition, the drug "De-nol" contains bismuth oxide. De-nol and its antiulcer activity are associated with an inhibitory (bactericidal) effect on Helicobacter pylori. De-nol is able to envelop the mucous membrane, forming a protective shell of bismuth compounds on ulcerative and erosive defects. The drug has an anti-inflammatory effect, increases the activity of protective factors. This is achieved by increasing the formation of prostaglandins, gastric mucus and bicarbonate. In areas of a ulcerative or erosive defect, De-nol causes an increase in tissue regeneration. The drug inhibits pepsin activity.
Bismuth does not go beyond the digestive tract, a small amount is absorbed into the blood. The drug is excreted through the intestines.
The medicine "De-nol" is used in the treatment of ulcerative lesions of the stomach and duodenum, during the period of exacerbation, with chronic gastritis and gastroduodenitis, gastroenteritis and functional digestive disorders.
The drug is prescribed for the treatment of these diseases in adults and children, starting at the age of four. Calculation of the dosage of the drug in childhood is performed per kilogram of body weight of the child. Reception is carried out half an hour before meals, washed down with a small amount of water. The duration of treatment is determined by the nature of the disease and is usually one to two months.
The medicine is usually well tolerated. Adverse reactions are rare and can be expressed in dyspeptic symptoms and stool disorders, with prolonged use, the development of encephalopathy is possible.
The drug can not be taken with the effects of renal failure, pregnancy and lactation.
Due to the possibility of cumulation of bismuth, the drug should not exceed the specified period and be combined with other bismuth-containing drugs.